Document Detail

Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
MedLine Citation:
PMID:  17970639     Owner:  NLM     Status:  MEDLINE    
Recognition of cancer-specific antigens resulted in development of monoclonal antibodies as treatments for various neoplasms including chronic lymphocytic leukemia (CLL). Two monoclonal antibodies, alemtuzumab and rituximab, have been extensively studied, as monotherapy or in combination, in patients with various clinical stages of CLL. Alemtuzumab, particularly when combined with fludarabine-based chemotherapy, sequentially or concomitantly, represents a promising therapeutic approach that results in improved efficacy by further reducing levels of residual disease in previously untreated or relapsed/refractory CLL. On the other hand, single-agent rituximab has limited activity by itself, even at very high doses, and seldom induces complete remissions. However, rituximab is feasible to combine with conventional chemotherapies such as purine analogs, alkylating chemotherapy and/or alemtuzumab. Newer monoclonal antibodies are already showing activity in relapsed/refractory CLL and will eventually be evaluated in combinations with conventional chemotherapy, or with already established antibodies. Modern definitions for assessment of responses such as minimal residual disease negativity (MRD negativity) are emerging and, consequently, development of assays capable of measuring such responses. MRD negativity should become the primary objective of clinical trials when evaluating treatment interventions in patients with CLL. The future of monoclonal antibodies for treatment of CLL is bright.
Mohamed A Kharfan-Dabaja; Rabih Fahed; Mohamad Hussein; Edgardo S Santos
Related Documents :
24377019 - Hdr-plesiotherapy for the treatment of anogenital extramammary paget's disease.
18473009 - Oblimersen for the treatment of patients with chronic lymphocytic leukemia.
24750519 - Recurrent immature teratoma of the ovary with long-term disease-free interval.
23695509 - The influence of early diagnosis of endometrioid endometrial cancer on disease stage an...
24991209 - Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma.
23466569 - Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligibl...
21470549 - The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in brca2-mut...
15383869 - Prognostic factors for early gastric cancer in france: cox regression analysis of 332 c...
2426519 - The treatment of nonseminomatous testicular tumors: 15 years experience.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  16     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-31     Completed Date:  2007-11-13     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1799-815     Citation Subset:  IM    
H. Lee Moffitt Cancer Center and Research Institute, Division of Blood and Marrow Transplantation, 12902 Magnolia Drive, BMT-WCB, Tampa, FL 33612, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neoplasm / therapeutic use
Antineoplastic Agents / therapeutic use*
Hematopoietic Stem Cell Transplantation
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Monoclonal, Murine-Derived; 0/Antibodies, Neoplasm; 0/Antineoplastic Agents; 0/rituximab; 3A189DH42V/alemtuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The hypocretin/orexin receptor: therapeutic prospective in sleep disorders.
Next Document:  Fatty acid synthase inhibitors: new directions for oncology.